Process for the selective formation of disulfide bridges in polypeptides and therapeutic compositions

Claim 2

Process for the selective formation of at least two disulfide bridges in a polypeptide which process comprises treating a polypeptide starting material carrying at least four SH-groups to mask at least one of two of said SH-groups, intended to form a first disulfide bridge, with a p-methoxybenzyl protective group and to mask at least one SH-group of each further pair of SH-groups intended to form one or more further disulfide bridges, with an acetamido methyl protective group, then splitting off said p-methoxybenzyl protective group with pyridine-polyhydrogen fluoride in the presence of anisol to produce that first disulfide bridge, and then treating the polypeptide with iodine in an acid solution to produce said disulfide bridge-containing polypeptide by forming said one or more further disulfide bridges.

Claim 3

Process as claimed in claim 1 wherein the formation of two or more disulfide bridges is conducted in the presence of already existing disulfide bridges.

Claim 4

Process as claimed in claim 1 wherein said polypeptide is a synthetic polypeptide.

Claim 5

Process as claimed in claim 1 wherein said polypeptide is a natural polypeptide.

Claim 6

Process as claimed in claim 2, wherein an already existing disulfide bridge is formed by reductive splitting-off of two tertiary butyl mercapto protective groups, protecting two further SH-groups carried by said polypeptide starting material, with tributyl phosphane under inert gas and selective oxidation with oxygen prior to forming the said first and further disulfide bridges.

Claim 7

Process for the selective formation of at least three disulfide bridges in a polypeptide which process comprises treating a polypeptide starting material, carrying at least 6 SH-groups, to mask two of said SH-groups intended to form a first disulfide bridge with tertiary butyl mercapto protective groups, to mask at least one of two further of said SH-groups, intended to form a second disulfide bridge, with an acetamido methyl protective group, and to mask at least one SH-group of each further pair of SH-groups, intended to form one or more further disulfide bridges, with an acetamido methyl protective group, then splitting off said two tertiary butyl mercapto protective groups with tributyl phosphane under innert gas and selective oxidation with oxygen, thereby forming that first disulfide bridge, then splitting-off said p-methoxybenzyl protective group with pyridine-polyhydrogen fluoride in the presence of anisol to produce that second disulfide bridge, and then treating the polypeptide with iodine in an acid solution to produce said disulfide bridge-containing polypeptide by forming said one or more further disulfide bridges.

Claim 8

Process for the selective formation of at least three disulfide bridges in a polypeptide which process comprises treating a polypeptide starting material, carrying at least 6 SH-groups, to mask two of said SH-groups intended to form a first disulfide bridge with tertiary butyl mercapto protective groups, to mask at least one of two further of said SH-groups, intended to form a second disulfide bridge, with an acetamido methyl protective group, and to mask at least one SH-group of each further pair of SH-groups, intended to form one or more further disulfide bridges, with an acetamido methyl protective group, then splitting off said two tertiary butyl mercapto protective groups with tributyl phosphane under innert gas and selective oxidation with oxygen, thereby forming that first disulfide bridge, then splitting-off said p-methoxybenzyl protective group with pyridine-polyhydrogen fluoride in the presence of anisol to produce that second disulfide bridge, and then treating the polypeptide with iodine in an acid solution to produce said disulfide bridge-containing polypeptide by forming said one or more further disulfide bridges.

Claim 9

Process as claimed in claim 1 wherein active human insulin is prepared by reacting a synthetic insulin A-chain having an acetamido methyl protective group in the A 7 -position and a p-methoxybenzyl protective group in the A 20 -position and with an equimolar quantity of synthetic or natural reduced insulin B-chain.

Claim 10

Process as claimed in claim 7 wherein an insulin B-chain is used having an acetamido methyl protective group in the B 7 -position and a p-methoxybenzyl protective group in the B 19 -position.

Claim 11

Process as claimed in claim 7 wherein a synthetic insulin A-chain is used in which the small interachenaric disulfide ring has been formed by reductive splitting-off of the tertiary butyl mercapto protective groups in the A 6 - and A 11 -positions with tributyl phosphane under nitrogen and selective oxidation with air.

Claim 12

Process as claimed in claim 7 wherein the B-chain of bovine insulin is used as the natural insulin, modified at the C-terminus.

Claim 13

Process as claimed in claim 7 wherein A 6 -A 7 , A 11 -B 7 -cystine insulin is prepared from synthetic A 6 -A 7 insulin A-chain having an acetamido methyl protective group in the A 20 -position and a p-methoxybenzyl protective group in the A 11 -position.

Claim 14

Process as claimed in claim 1 wherein A 6 -A 7 , A 11 -B 7 -cystine insulin is prepared from synthetic A 6 -A 7 insulin A-chain having an acetamido methyl protective group in the A 11 -position and a p-methoxybenzyl protective group in the A 20 -position.

Claim 15

Process as claimed in claim 1 wherein the disulfide bridge formation is effected by oxidation with iodine in 30% acetic acid.

Claim 16

Process as claimed in claim 1 wherein the splitting off the p-methoxybenzyl protective group is carried out in pyridine polyhydrogen fluoride (HF/pyridine) as solvent and reagent.

Claim 17

Process as claimed in claim 1 wherein antiparallel A 6 -A 11 , A 7 -B 19 , A 20 -B 7 -cystine insulin is produced by reacting a natural or synthetic A 6 -A 11 insulin A-chain having an acetamido methyl protective group in the A 7 -position and a p-methoxybenzyl protective group in the A 20 -position, with a natural or synthetic insulin B-chain in reduced form or having an acetamido methyl protective group in the B 19 -position and a p-methoxybenzyl protective group in the B 7 -position.

Claim 18

Process as claimed in claim 1 wherein antiparallel A 6 -A 11 , A 7 -B 19 , A 20 -B 7 -cystine insulin is produced by reacting a natural or synthetic A 6 -A 11 insulin A-chain having an acetamido methyl protective group in the A 20 -position and a p-methoxybenzyl protective group in the A 7 -position, with a natural or synthetic insulin B-chain in reduced form having an acetamido methyl protective group in the B 7 -position and a p-methoxybenzyl protective group in the B 19 -position.

Claim 19

Process as claimed in claim 1 wherein antiparallel A 6 -A 11 , A 7 -B 19 , A 20 -B 7 cystine insulin is produced by reacting a synthetic A 7 -A 11 insulin A-chain having an acetamido methyl protective group in the A 6 -position and a p-methoxybenzyl protective group in the A 20 -position with a natural or synthetic insulin B-chain in reduced form having an acetamido methyl protective group in the B 19 -position and a methoxybenzyl protective group in the B 7 -position.

Claim 20

Process as claimed in claim 1 wherein antiparallel A 6 -A 11 , A 7 -B 19 , A 20 -B 7 -cystine insulin is produced by reacting a synthetic A 6 -A 11 insulin A-chain having an acetamido methyl protective group in the A 20 -position and a p-methoxybenzyl protective group in the A 7 -position with a natural or synthetic insulin B-chain in reduced form or having an acetamido methyl protective group in the B 7 -position and a p-methoxybenzyl protective group in the B 19 -position.

Claim 21

Process as claimed in claim 1 wherein antiparallel A 6 -A 11 , A 7 -B 19 , A 20 -B 7 -cystine insulin is produced by reacting a synthetic A 6 -A 11 insulin A-chain having an acetamido methyl protective group in the A 7 -position and a p-methoxybenzyl protective group in the A 20 -position with a natural or synthetic insulin B-chain in reduced form having an acetamido methyl protective group in the B 19 -position and a p-methoxybenzyl protective group in the B 7 -position.

Claim 22

Process as claimed in claim 1 wherein antiparallel A 6 -A 7 , A 11 -B 19 , A 20 -B 7 -cystine insulin is produced by reacting a synthetic A 6 -A 7 insulin A-chain having an acetamido methyl protective group in the A 20 -position and a p-methoxybenzyl protective group in the A 11 -position with a natural or synthetic insulin B-chain in reduced form or having an acetamido methyl protective group in the B 7 -position and a p-methoxybenzyl protective group in the B 19 -position.

Claim 23

Process as claimed in claim 1 wherein antiparallel A 6 -A 11 , A 7 -B 19 , A 20 -B 7 -cystine insulin is produced by reacting a natural or synthetic insulin A-chain, with the intrachenaric disulfide ring in the A 6 -A 11 -position, the A 7 -A 11 -position or in the A 6 -A 7 -position in a parallel or antiparallel manner with a natural or synthetic insulin B-chain in reduced form or having acetamido methyl protective groups and a p-methoxybenzyl protective groups, where the specified A-chain by a reactive anchor bond is linked to a polymeric carrier.

Claim 24

Process as claimed in claim 21 wherein polystyrene cross-linked with divinylbenzene is used as the polymeric carrier.

Claim 25

Process as claimed in claim 22 wherein a polystyrene gel is used, which is cross-linked with 0.1% to 0.8% divinylbenzene.

Claim 26

Process as claimed in claim 23 wherein 0.5 divinylbenzene is used.